Corbus Pharmaceuticals Holdings, Inc. reported Q4 and full year 2025 financial results, including a Q4 net loss of $20.6 million ($1.25 per share) and cash of $163.3 million extending runway into 2028, alongside promising CRB-701 oncology data and CRB-913 obesity trial updates with key readouts expected in 2026.
Key takeaways
Q4 2025 net loss $20.6 million or $1.25 per basic and diluted share vs $9.5 million or $0.78 per share in Q4 2024
Full year 2025 net loss $78.5 million or $5.90 per share vs $40.2 million or $3.68 per share in 2024
Cash, cash equivalents, and investments $163.3 million as of December 31, 2025, funding operations into 2028
CRB-701 unconfirmed ORR at 3.6 mg/kg: HNSCC 47.6%, cervical cancer 37.5%, bladder 55.6% per ESMO 2025 data
CRB-913 14-day weight loss 2.9% placebo-adjusted at 150 mg/day with favorable GI safety in Phase 1a
Completed $75 million public offering in Q4 2025
CRB-913 12-week study (n=240) completion expected summer 2026; CRB-701 mid-2026 monotherapy data